These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15676296)

  • 1. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".
    Schlehuber S; Skerra A
    Drug Discov Today; 2005 Jan; 10(1):23-33. PubMed ID: 15676296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.
    Schiefner A; Skerra A
    Acc Chem Res; 2015 Apr; 48(4):976-85. PubMed ID: 25756749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticalins as alternative binding proteins for therapeutic use.
    Skerra A
    Curr Opin Mol Ther; 2007 Aug; 9(4):336-44. PubMed ID: 17694446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.
    Schlehuber S; Skerra A
    Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalins in drug development.
    Schlehuber S; Skerra A
    BioDrugs; 2005; 19(5):279-88. PubMed ID: 16207069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D.
    Vogt M; Skerra A
    Chembiochem; 2004 Feb; 5(2):191-9. PubMed ID: 14760740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands.
    de Wolf FA; Brett GM
    Pharmacol Rev; 2000 Jun; 52(2):207-36. PubMed ID: 10835100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipocalins as a scaffold.
    Skerra A
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):337-50. PubMed ID: 11058774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC
    Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based lead discovery: leads by design.
    Carr RA; Congreve M; Murray CW; Rees DC
    Drug Discov Today; 2005 Jul; 10(14):987-92. PubMed ID: 16023057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered systems for detection and discovery of nuclear hormone-like compounds.
    Gillies AR; Skretas G; Wood DW
    Biotechnol Prog; 2008; 24(1):8-16. PubMed ID: 18081307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative ligand-binding analysis of ten human lipocalins.
    Breustedt DA; Schönfeld DL; Skerra A
    Biochim Biophys Acta; 2006 Feb; 1764(2):161-73. PubMed ID: 16461020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single lysyl residue defines the binding specificity of a human odorant-binding protein for aldehydes.
    Tcatchoff L; Nespoulous C; Pernollet JC; Briand L
    FEBS Lett; 2006 Apr; 580(8):2102-8. PubMed ID: 16546182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.